Search PubMed⌕ Search

Biomedical subjects

B Sopková

Publications and source records attributed to B Sopková.

12 recordsLinked to original sources
PubMed1987

The excretion of urinary enzymes, proteins and creatinine in patients receiving cisplatinum.

The sensitive parameters of tubular nephrotoxicity during 4-day chemotherapy with new combination schedule of cisplatinum and 5-fluorouracil were followed. The determinations of tubular enzymes beta-glucuronidase (GRS) and gamma-glutamyltransferase (GMT) in 24 hours urine, the excretion of creatinine and proteinuria were assayed before therapy and during 4 consecutive days of treatment. We recorded the significant increase of protein excretion and only slight increase of GMT and GRS activities after chemotherapy. The decrease of the creatinine excretion on the 3rd day of therapy was not statistically significant. Simultaneously followed serum creatinine and urea levels proved the elevation of creatinine only in 1 patient (the 1st grade according WHO classification). Our results suggest that the performed regime of chemotherapy produces only very low nephrotoxicity comparing to the 1-day administration of cisplatinum. These conclusions are confirmed also by the former examinations of GRS activities in cisplatinum therapy.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1984

[Acyclovir].

Explore the source record for details and available documents.

Acyclovir↗
PubMed1984

[Tiapride].

Explore the source record for details and available documents.

Analgesia↗
PubMed1984

CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer.

Fourteen patients with advanced carcinoma of the breast were treated with CAP combination therapy. An objective therapeutic response (partial remissions with a mean duration of 6.3 months) was achieved in 6 of 13 evaluated patients. This response was observed in soft tissue metastases. Nausea and vomiting were found to be the most frequent undesirable side effects in all patients and could not be avoided by administration of antiemetics. In 2 patients mild nephrotoxicity was found without any effects on further therapy. The results of this study were considered as promising; a definitive assessment of the CAP regimen is expected to come from a randomized study which started in the CMEA countries in 1983.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1979

Comparison of the excretion of different types of melanogens in the melanoma patients.

Urinary melanogens are indolic and phenolic compounds which are excreted in an elevated amount in the urine of melanoma patients. Urinary melanogens can be divided into two principal groups according to their behavior during Thormählen test--Thormählen positive melanogens (TPM) and Thormählen negative melanogens (TNM). When comparing TPM and TNM (represented by homovanillic and vanillactic acids) urinary excretion in stage III of melanoma patients we have found two significantly different relations for melanogens excretion, i. e. predominating TPM urinary excretion in melanotic forms of melanomas and predominating homovanillic acid and vanillactic acid urinary excretion in amelanotic forms of melanomas. We assumed that it could be an indirect evidence of the different catalytic activity of either cresolase or catecholase activities of tyrosinase.

Eye Neoplasms↗
PubMed1979

Histologic changes in the human skin melanoma after intratumorous treatment with BCG.

Twenty six patients with malignant skin melanomas were treated with an intratumorous injection of 0.1 ml BCG applicated in certain time intervals. Histologic changes in tumor tissue starting with dystrophy and necrosis of the cells and ending with the formation of a granular tissue replacing the tumor are described. In one case the untreated satellite localized 2 cm from the injected tumor disappeared. The results indicate that the reaction of the cells on the applicated vaccine varied. In some tumors dystrophic changes and necroses were very large, in others they were of a lesser extent, but in all the process ended with the formation of a granular tissue. The mechanism of the action of BCG is discussed. For the time being, it seems that the intratumorous application of BCG is a useful adjuvant therapy.

BCG Vaccine↗
PubMed1976

Intralesional BCG application in malignant melanoma.

Immunotherapy of malignant melanoma with BCG may be divided into two basic groups: 1. treatment of minimum residual disease. 2. direct intralesional application of BCG. In 19 patients with a histologically confirmed malignant melanoma, direct intralesional application of BCG was used to treat relapsing patients. In 10 of the 19 patients (group A) the relapse was confined to the primary region without signs of distant dissemination. In the remaining 9 patients (group B) signs of the lesion were present prior to BCG application. Our clinical and cytological evaluation bore on local reactions, systemic side reactions and response of non-injected lesions. In patients without signs of distant dissemination, local regression, characterized by a flattening and disappearance of lenticular metastases with scar formation, was achieved in 8/10 patients, while in the noninjected lesions, regression was noted in only 4/10 patients. In 4 patients of group A complete remission lasting 4-6 months was achieved. In the group of patients with signs of distant dissemination, local regression was observed in 6/9, while noninjected lesion regressed in only 1/9. Systemic response to BCG was characterized by febrile reactions with, in the majority of the patients, nausea till vomiting, muscular pain, pain of joints. In the majority of the patients the reaction passed away within 24 hr. A pretreatment with antipyretic and antihistaminic drugs proved of great help. The effect of BCG on the subsequent fate and survival of the patients is not discussed.

Administration, Topical↗